HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ: NRXP), has set its sights on acquiring a network of interventional psychiatry clinics specializing in ketamine treatments. The company has secured financing valued at $30 million from a reputable lender to fuel this expansion, with plans to finalize the acquisition of five operational clinics in the Western United States. These clinics, which generate over $10 million in annual revenue, are dedicated to treating conditions such as suicidal depression, treatment-resistant depression (TRD), and PTSD.
HOPE Therapeutics is committed to offering a patient-centric approach by integrating pharmaceutical therapies with FDA-approved technologies like Transcranial Magnetic Stimulation (TMS). Co-CEOs Jonathan Javitt and Matthew Duffy have expressed their enthusiasm for this strategic move, emphasizing its significance. “We are thrilled to embark on this pivotal journey towards establishing a network of clinics that can deliver the highest quality of care,” they noted.
The company aims to achieve annualized revenues of $100 million by mid-2025 through the continued acquisition of clinics and envisions expanding its operations to the United States, France, and the United Kingdom.
The Surging Popularity of Ketamine Clinics and Treatments
In recent years, ketamine, originally recognized as an anesthetic, has garnered widespread attention for its off-label use in addressing mental health conditions such as depression, PTSD, and TRD. Its rapid-acting properties have propelled the rise of ketamine-assisted therapies, offering relief in cases where traditional antidepressants have proven ineffective. Ongoing research has led to the development of refined treatments, with innovative delivery methods like nasal sprays, topical creams, and patient-controlled infusions further enhancing accessibility and efficacy.
Photo: Courtesy of Sonis Photography via Shutterstock
